Status:
COMPLETED
An International Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
Lead Sponsor:
Corcept Therapeutics
Conditions:
Major Depressive Disorder
Psychotic Disorders
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physic...
Eligibility Criteria
Inclusion
- Completed participation through Day 56 in Corcept Therapeutics Protocol C-1073-09
- Are 18 to 75 years of age
- Have a diagnosis of major depressive disorder with psychotic features (DSM-IV 296.24 or 296.34)
- Are able to provide written informed consent
Exclusion
- Have a major medical problem
- Have a history of an allergic reaction to CORLUX (C-1073, mifepristone)
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2006
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT00128505
Start Date
August 1 2005
End Date
November 1 2006
Last Update
February 15 2012
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Georgy Koychev M.D.
Sofia, Bulgaria
2
Luchezar G Hranov M.D.
Sofia, Bulgaria
3
Svetlozar H Haralanov Ph.D.
Sofia, Bulgaria
4
Vihra Milanova M.D.
Sofia, Bulgaria